arrow
K

Karl S. Lang

University of Duisburg-Essen
H指数:66
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mutations at Positions 181 and 185 Within the LCMV GP Protein Increase Tumor Cell Infectivity, Limit Induction of Type I Interferon, and Accelerate T Cell Activation

LCMV GP蛋白中181和185位点的突变增加肿瘤细胞感染性,限制I型干扰素的诱导,并加速T细胞激活

2026-09-120
OA
Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma

基于靶向和表观遗传的联合治疗通过稳定胰腺导管腺癌GATA6-dependent MHCI表达来增强抗肿瘤免疫力

2026-02-060
OAAI
Acid ceramidase regulates CD8+ T-cell exhaustion via type I interferon-mediated upregulation of PD-L1

酸神经酰胺酶通过I型干扰素介导的PD-L1上调来调节CD8+ T细胞耗竭

2025-12-090
OAAI
Optimized arenaviruses with tumor-tropic mutations promote safe anti-tumor efficacy via sustainable immune modulatory properties

经过优化的具有肿瘤趋向性突变的沙粒病毒通过可持续的免疫调节特性促进安全的抗肿瘤效果。

2025-10-130
OAAI
During early stages of cancer, neutrophils initiate anti-tumor immune responses in tumor nodes

在癌症的早期阶段,中性粒细胞在肿瘤淋巴结中启动抗肿瘤免疫反应

2022-08-0143
OA
Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression

颗粒蛋白前体通过调节MHCI表达介导胰腺导管腺癌的免疫逃避

2022-01-1040
OAAI
SIRT1-mediated deacetylation of FOXO3a transcription factor supports pro-angiogenic activity of interferon-deficient tumor-associated neutrophils

FOXO3a转录因子的SIRT1-mediated去乙酰化支持干扰素缺陷的肿瘤相关中性粒细胞的促血管生成活性

2021-11-2419
OA